CompanyBEAMNasdaqCambridge, MA

Beam Therapeutics Inc.

Beam Therapeutics develops base editing, a gene editing technology designed to make precise single-base changes in DNA without double-stranded breaks.

Stories only

SEC EDGAR ClinicalTrials.gov beamtx.com

10-QSep 2Latest SEC filing, period to Jun 30

Aug 6Latest story

August 2026

Beam doses first patient in pivotal BEAM-302 cohort, updates PKU and sickle cell timelines

Aug 4Quarterly updateBeam Therapeutics Inc.